MARKET

EDSA

EDSA

Edesa Biotech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.64
-0.05
-0.88%
After Hours: 5.64 0 0.00% 17:50 03/02 EST
OPEN
5.69
PREV CLOSE
5.69
HIGH
5.86
LOW
5.61
VOLUME
152.17K
TURNOVER
--
52 WEEK HIGH
19.10
52 WEEK LOW
1.580
MARKET CAP
74.33M
P/E (TTM)
-6.6967
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Edesa Biotech Announces Closing of $10 Million Bought Deal Offering of Common Shares
TORONTO, ON / ACCESSWIRE / March 2, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing of its previously announced underwritten public offeri...
ACCESSWIRE · 11h ago
Xtant Medical, Sensus Healthcare leads healthcare gainers; Tricida, Recro Pharma among major losers
Gainers: Xtant Medical (XTNT) +54%, Sensus Healthcare (SRTS) +34%, Rubius Therapeutics (RUBY) +23%, Select Medical (SEM) +18%, Dynavax Technologies (DVAX) +18%.Losers: Tricida (TCDA) -32%, Recro Pharma (REPH) -27%, Zynex (ZYXI) -17%, NLS Pharmaceutics (NLS...
Seekingalpha · 4d ago
DASH, SPCE among premarket losers
Tengasco (TGC) -28% on reverse stock split announcement.Tricida TCDA -26% after FDA rejected appeal for chronic kidney disease trial.TDH Holdings (PETZ) -16%.The9 NCTY -16%.Pintec Technology (PT) -15%.United States Antimony (UAMY) -4%.Virgin Galactic SPCE ...
Seekingalpha · 4d ago
The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25)
Benzinga · 4d ago
Stocks Mixed in Choppy Midday as Tightening Rates Weigh
MT Newswires · 4d ago
Edesa Biotech Increased Previously Announced Bought Deal Offering of Common Shares to $10M; Priced 1.56M Shares @$6.40/Share
Edesa Biotech, Inc. (NASDAQ: EDSA) announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 1,562,500 common shares of Edesa, at a price to the public...
Benzinga · 4d ago
Edesa Bio secures $10M capital raise
Edesa Biotech's (EDSA) underwriter has increased the size of the previous offering and purchase ~1.6M common shares at $6.40/share.Expected gross proceeds are $10M.Underwriter's over-allotment is an additional ~234.4K shares. Net
Seekingalpha · 5d ago
Edesa Biotech Increases Previously Announced Bought Deal Offering of Common Shares to $10.0 Million
ACCESSWIRE · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EDSA. Analyze the recent business situations of Edesa Biotech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EDSA stock price target is 17.00 with a high estimate of 18.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 19
Institutional Holdings: 231.66K
% Owned: 1.76%
Shares Outstanding: 13.18M
TypeInstitutionsShares
Increased
3
15.62K
New
4
93.46K
Decreased
3
46.71K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.03%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Non-Executive Chairman/Independent Director
Sean MacDonald
President
Michael Brooks
Chief Executive Officer/Secretary/Director
Pardeep Nijhawan
Chief Financial Officer
Kathi Niffenegger
Director
Frank Oakes
Independent Director
Lorin Johnson
Independent Director
Paul Pay
Independent Director
Carlo Sistilli
Independent Director
Peter van der Velden
  • Dividends
  • Splits
  • Insider Activity
No Data
About EDSA
Edesa Biotech Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing and commercializing clinical-stage drugs for dermatological and gastrointestinal indications. Its lead product candidate, EB01, is an sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD). Its pipeline also includes EB02 and EB04. EB02, an sPLA2 inhibitor, is being developed as a treatment for patients with hemorrhoids disease (HD). EB04 is being developed for anal fissures. It is also focused on developing biologic drug candidates for therapeutic, prophylactic and diagnostic applications.

Webull offers kinds of Edesa Biotech Inc stock information, including NASDAQ:EDSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDSA stock methods without spending real money on the virtual paper trading platform.